Auckland, Grafton Clinical Trials

A listing of Auckland, Grafton clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 157 clinical trials
Re-Irradiation of Progressive or Recurrent DIPG

This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)

  • 24 Mar, 2022
  • 18 locations
Lung UltrasouNd Guided Surfactant Therapy in Preterm Infants (LUNG Study) (LUNG)

The investigators hypothesized that the use of lung ultrasound (LU) for measuring RDS severity and deciding surfactant treatment thresholds might decrease the incidence of early and late sequelae in the study group. Thus, a timely surfactant therapy would eventually improve short (e.g. Need of mechanical ventilation in the first 3 …

  • 21 Jul, 2022
  • 12 locations
Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation (Cess@Tion) (Cess@Tion)

This research focuses on maximizing the benefits of proven smoking cessation interventions to support people who smoke to quit, as part of the strategy to help New Zealand become smoke-free. A large, pragmatic community-based clinical trial is planned which draws on 15 years of smoking cessation research undertaken by the …

nicotine replacement
tobacco smoke
Accepts healthy volunteers
  • 25 May, 2022
  • 1 location
Preventing Adverse Cardiac Events in COPD

A double-blind, randomised controlled trial in participants with COPD to assess the efficacy of proactive treatment of cardiac risk in people with COPD. We hypothesise that treating known and undiagnosed CVD in COPD participants will improve both cardiac and respiratory outcomes.

heart failure
copd exacerbation
  • 25 Jan, 2021
  • 17 locations
Targeted Education ApproaCH to Improve Peritoneal Dialysis Outcomes Trial (TEACH-PD)

For many patients peritoneal dialysis (PD) is the preferred form of dialysis to treat kidney disease as it provides greater flexibility and the ability to dialyse at home. However, PD use in Australia has been decreasing over the last 10 years. A big reason for this drop is the risk …

  • 19 Feb, 2022
  • 39 locations
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of intrathecal (IT) WVE-004 in adult patients with C9orf72-associated ALS or FTD. To participate in the study, patients must have a documented mutation (GGGGCC [G4C2] repeat expansion) in the first intronic region …

primary lateral sclerosis
frontotemporal dementia
frontotemporal lobar degeneration
  • 27 Jul, 2022
  • 15 locations
The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study (EASY-AS)

Aortic stenosis (AS) affects approximately 5% of individuals >65 years old, with ~3% of people >75 years having moderate to severe disease. The prevalence of AS is rising rapidly due to an ageing population and is projected to double in the next two decades. Increasingly clinicians face the dilemma of …

aortic valve replacement
angina pectoris
  • 28 Feb, 2022
  • 22 locations
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (EPO-TRAUMA)

The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and severe disability at six months in critically ill trauma patients. 2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting to the …

  • 11 Aug, 2022
  • 21 locations
Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT (MINOCA-BAT)

Myocardial infarction with non-obstructive coronary arteries" (MINOCA) occurs in 5-10% of all patients with AMI. There are neither any randomized clinical trials in MINOCA patients evaluating effects of secondary preventive treatments proven beneficial in patients with classic AMI, nor any treatment guidelines. The primary objective of this multi-national, multi-center pragmatic …

  • 04 Feb, 2022
  • 18 locations
Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) monotherapy in patients with PNH that are treatment naïve, or patients currently treated with eculizumab who still experience anemia and reticulocytosis, or patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent, …

reticulocyte count
complement inhibitor
platelet count
complement c5
  • 17 Jun, 2022
  • 8 locations